1. Home
  2. ELUT vs ZNTL Comparison

ELUT vs ZNTL Comparison

Compare ELUT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELUT
  • ZNTL
  • Stock Information
  • Founded
  • ELUT 2015
  • ZNTL 2014
  • Country
  • ELUT United States
  • ZNTL United States
  • Employees
  • ELUT N/A
  • ZNTL N/A
  • Industry
  • ELUT Medical Specialities
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELUT Health Care
  • ZNTL Health Care
  • Exchange
  • ELUT Nasdaq
  • ZNTL Nasdaq
  • Market Cap
  • ELUT 88.4M
  • ZNTL 105.8M
  • IPO Year
  • ELUT 2020
  • ZNTL 2020
  • Fundamental
  • Price
  • ELUT $2.09
  • ZNTL $1.99
  • Analyst Decision
  • ELUT Strong Buy
  • ZNTL Buy
  • Analyst Count
  • ELUT 2
  • ZNTL 7
  • Target Price
  • ELUT $8.00
  • ZNTL $8.46
  • AVG Volume (30 Days)
  • ELUT 29.0K
  • ZNTL 784.9K
  • Earning Date
  • ELUT 08-14-2025
  • ZNTL 08-06-2025
  • Dividend Yield
  • ELUT N/A
  • ZNTL N/A
  • EPS Growth
  • ELUT N/A
  • ZNTL N/A
  • EPS
  • ELUT N/A
  • ZNTL N/A
  • Revenue
  • ELUT $23,683,000.00
  • ZNTL $26,865,000.00
  • Revenue This Year
  • ELUT $20.10
  • ZNTL N/A
  • Revenue Next Year
  • ELUT $85.89
  • ZNTL N/A
  • P/E Ratio
  • ELUT N/A
  • ZNTL N/A
  • Revenue Growth
  • ELUT N/A
  • ZNTL N/A
  • 52 Week Low
  • ELUT $1.61
  • ZNTL $1.01
  • 52 Week High
  • ELUT $5.12
  • ZNTL $5.44
  • Technical
  • Relative Strength Index (RSI)
  • ELUT 52.40
  • ZNTL 78.59
  • Support Level
  • ELUT $1.96
  • ZNTL $1.55
  • Resistance Level
  • ELUT $2.30
  • ZNTL $1.70
  • Average True Range (ATR)
  • ELUT 0.14
  • ZNTL 0.12
  • MACD
  • ELUT 0.01
  • ZNTL 0.05
  • Stochastic Oscillator
  • ELUT 45.03
  • ZNTL 91.43

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: